Literature DB >> 8285815

Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis.

L Caregaro1, F Menon, P Angeli, P Amodio, C Merkel, A Bortoluzzi, F Alberino, A Gatta.   

Abstract

BACKGROUND: Several studies carried out in a limited number of patients demonstrated a wide range of overestimation of glomerular filtration rate (GFR) by serum creatinine level and creatinine clearance (Ccr) in liver disease.
METHODS: We simultaneously evaluated Ccr, inulin clearance, and predicted GFR calculated from serum creatinine level in 56 cirrhotic patients. Inulin clearance was considered the gold standard for GFR evaluation.
RESULTS: The sensitivity of serum creatinine level, predicted GFR, and Ccr in detecting renal failure was 18.5%, 51%, and 74%, respectively. On the basis of inulin clearance, patients were divided into two groups: those with normal GFR (mean, 106 +/- 34 mL/min per 1.73 m2) (group 1, 29 patients) and those with reduced GFR (mean, 56 +/- 19 mL/min per 1.73 m2) (group 2, 27 patients). Predicted GFR and Ccr were accurate markers of GFR in group 1 patients, while both overestimated GFR by about 50% in group 2 patients. An increased tubular secretion of creatinine accounted for the disparity between Ccr and inulin clearance in these patients.
CONCLUSIONS: Our results indicate that renal failure is greatly underestimated on the basis of serum creatinine level and Ccr in cirrhotic patients. Clinical implications of this observation include excessive dosage of potentially nephrotoxic drugs and failure to recognize renal impairment induced by such medical treatments as diuretic therapy or paracentesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8285815

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  73 in total

Review 1.  Bacterial infections in end-stage liver disease: current challenges and future directions.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Florence Wong; K Rajender Reddy; Patrick S Kamath
Journal:  Gut       Date:  2012-06-03       Impact factor: 23.059

2.  Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.

Authors:  N Gara; X Zhao; M T Collins; W H Chong; D E Kleiner; T Jake Liang; M G Ghany; J H Hoofnagle
Journal:  Aliment Pharmacol Ther       Date:  2012-04-16       Impact factor: 8.171

Review 3.  GFR Estimating Equations and Liver Disease.

Authors:  Tomasz Beben; Dena E Rifkin
Journal:  Adv Chronic Kidney Dis       Date:  2015-09       Impact factor: 3.620

Review 4.  Hepatorenal syndrome.

Authors:  Sharon Turban; Paul J Thuluvath; Mohamed G Atta
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

5.  Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation.

Authors:  Giuseppe Cullaro; Joseph F Pisa; Robert S Brown; Gebhard Wagener; Elizabeth C Verna
Journal:  Transplantation       Date:  2018-05       Impact factor: 4.939

6.  Evaluation of Vancomycin Dosing in Patients With Cirrhosis: Beginning De-Liver-ations about a New Nomogram.

Authors:  Randolph E Regal; Steven P Ren; Gregory Paige; Cesar Alaniz
Journal:  Hosp Pharm       Date:  2018-04-26

Review 7.  Renal dysfunction in cirrhosis.

Authors:  Nathalie H Urrunaga; Ayse L Mindikoglu; Don C Rockey
Journal:  Curr Opin Gastroenterol       Date:  2015-05       Impact factor: 3.287

Review 8.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

9.  The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.

Authors:  Y-L He; R Sabo; J Campestrini; Y Wang; M Ligueros-Saylan; K C Lasseter; S C Dilzer; D Howard; W P Dole
Journal:  Eur J Clin Pharmacol       Date:  2007-05-08       Impact factor: 2.953

Review 10.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.